This is a developing story. Please check back for updates. | After a tumultuous tenure marked by recent clashes with the ...

The top vaccine and biologics drug official in the U.S. Food and Drug Administration will step down in April. The agency made ...

Prasad’s departure marks another high-profile leadership change at the FDA, which is going through a period of significant change.

The controversial head of the U.S. Food and Drug Administration's vaccines and biologics unit, Vinay Prasad, will leave the ...

The Food and Drug Administration's embattled vaccine chief, Dr. Vinay Prasad, is once again leaving the agency — the second time in less than a year that he's departed after controversial decisions ...

Dr. Vinay Prasad drew criticism for overriding career scientists and rejecting drugs by companies seeking agency approval.

Rare disease biotech stocks pop on the news that Vinay Prasad, the FDA’s chief biologics regulator, will depart the FDA at the end of April; Sen. Ron Johnson launches an investigation into recent rare ...

Vinay Prasad, a top official at the Food and Drug Administration who has been at the center of recurring public controversies, is exiting the agency for a second time. Prasad will leave the FDA at the ...

Prasad’s planned departure, expected at the end of April, culminates a tumultuous term in which he reworked vaccine ...

By Kamal Choudhury and Michael Erman March 6 (Reuters) - The controversial head of the U.S. Food and Drug Administration's vaccines and biologics unit, Dr. Vinay Prasad, will leave the agency at the ...